公开(公告)号：US20220025059A1

公开(公告)日：2022-01-27

申请号：US17332578

申请日：2021-05-27

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.

公开(公告)号：US20240102094A1

公开(公告)日：2024-03-28

申请号：US18255524

申请日：2021-12-03

Applicant: AMGEN INC.

Inventor： Daniel C. ELLWANGER ,  Ian N. FOLTZ ,  Samuel A. HASSON

IPC: C12Q1/6883 ,  C12Q1/6874 ,  G01N33/68

CPC classification number: C12Q1/6883 ,  C12Q1/6874 ,  G01N33/6896 ,  C12Q2600/106 ,  C12Q2600/158 ,  G01N2800/2821 ,  G01N2800/52

Abstract: The present invention provides a method of treating a disease or conditions associated with a dysfunction of TREM2 in a human patient, such as Alzheimer's disease, comprising administering to the patient a TREM2 agonist. In another aspect, the invention provides a method of assaying a biological sample taken from a patient having Alzheimer's for biomarkers to determine potential benefit or if the disease has an increased probability of responding to treatment with a TREM2 agonist.

公开(公告)号：US20220204611A1

公开(公告)日：2022-06-30

申请号：US17449242

申请日：2021-09-28

Applicant: AMGEN INC.

Inventor： Ian N. FOLTZ ,  Shilpa SAMBASHIVAN ,  Irwin CHEN ,  Susie Miki HARRIS ,  Dora TOLEDO WARSHAVIAK ,  Ian DRIVER ,  Daniel LU

IPC: C07K16/28 ,  A61P25/28

Abstract: The present invention relates to antigen binding proteins, such as monoclonal antibodies, that specifically bind to and activate human triggering receptor expressed on myeloid cells-2 (TREM2) and pharmaceutical compositions comprising such antigen binding proteins. The agonist antigen binding proteins (e.g. antibodies) of the invention are capable of activating TREM2/DAP12 signaling in myeloid cells in the absence of Fc-mediated cross-linking of the antigen binding proteins. Methods of treating or preventing conditions associated with TREM2 loss of function, such as Alzheimer's disease and multiple sclerosis, using the antigen binding proteins are also described.

公开(公告)号：US20170275370A1

公开(公告)日：2017-09-28

申请号：US15387542

申请日：2016-12-21

Applicant: AMGEN INC.

Inventor： Junming YIE ,  Donghui SHI ,  David J. LLOYD ,  Jinghong WANG ,  Glenn N. SIVITS, JR. ,  Murielle M. VENIANT-ELLISON ,  Renee KOMOROWSKI ,  Neeraj AGRAWAL ,  Darren L. BATES ,  Brandon C. P. CLAVETTE ,  Ian N. FOLTZ ,  Shu-yin HO ,  Christopher MURAWSKY ,  Xiaoshan MIN ,  Zhulun WANG

IPC: C07K16/28 ,  A61K39/395 ,  A61K38/26 ,  A61K9/00

CPC classification number: C07K16/2869 ,  A61K9/0019 ,  A61K38/1703 ,  A61K38/26 ,  A61K39/3955 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2299/00 ,  C07K2317/21 ,  C07K2317/32 ,  C07K2317/33 ,  C07K2317/41 ,  C07K2317/52 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92 ,  A61K2300/00

Abstract: Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.